243 related articles for article (PubMed ID: 19802013)
21. Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells.
Borbone E; De Rosa M; Siciliano D; Altucci L; Croce CM; Fusco A
J Clin Endocrinol Metab; 2013 Jun; 98(6):E1031-40. PubMed ID: 23543665
[TBL] [Abstract][Full Text] [Related]
22. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.
Thakur VS; Gupta K; Gupta S
Carcinogenesis; 2012 Feb; 33(2):377-84. PubMed ID: 22114073
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
[TBL] [Abstract][Full Text] [Related]
24. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
Cao H; Cheng Y; You L; Qian J; Qian W
Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
[TBL] [Abstract][Full Text] [Related]
25. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.
Qu W; Kang YD; Zhou MS; Fu LL; Hua ZH; Wang LM
Urol Oncol; 2010; 28(6):648-54. PubMed ID: 19181544
[TBL] [Abstract][Full Text] [Related]
26. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
Venza I; Visalli M; Oteri R; Teti D; Venza M
Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
[TBL] [Abstract][Full Text] [Related]
27. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract][Full Text] [Related]
28. Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
Bhatia S; Krieger V; Groll M; Osko JD; Reßing N; Ahlert H; Borkhardt A; Kurz T; Christianson DW; Hauer J; Hansen FK
J Med Chem; 2018 Nov; 61(22):10299-10309. PubMed ID: 30365892
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation.
Rho JH; Kang DY; Park KJ; Choi HJ; Lee HS; Yee SB; Yoo YH
Int J Oncol; 2005 Aug; 27(2):465-71. PubMed ID: 16010429
[TBL] [Abstract][Full Text] [Related]
30. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
32. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
33. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
[TBL] [Abstract][Full Text] [Related]
36. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
Kaminskyy VO; Surova OV; Vaculova A; Zhivotovsky B
Carcinogenesis; 2011 Oct; 32(10):1450-8. PubMed ID: 21771726
[TBL] [Abstract][Full Text] [Related]
37. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
38. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Abaza MS; Bahman AM; Al-Attiyah RJ; Kollamparambil AM
Tumour Biol; 2012 Dec; 33(6):1951-72. PubMed ID: 23011889
[TBL] [Abstract][Full Text] [Related]
39. Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
Li L; Fan B; Zhang LH; Xing XF; Cheng XJ; Wang XH; Guo T; Du H; Wen XZ; Ji JF
Tumour Biol; 2016 Aug; 37(8):10269-78. PubMed ID: 26831669
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
